Ashwagandha has become one of the most popular adaptogens in Western wellness culture, marketed aggressively for stress reduction and cognitive support. What's often missing from that conversation is a rigorous accounting of where its bioactive compounds can cause harm — and this critical review attempts to fill that gap, identifying specific populations and mechanisms that deserve far more caution than current labeling reflects.
The review, published in Phytotherapy Research, synthesizes preclinical and clinical data on Withania somnifera's safety profile. Its withanolides, alkaloids, and sitoindosides — the very compounds credited with therapeutic effects — emerge as double-edged. Hepatotoxicity appears to be among the most clinically significant concerns: cytochrome P450 enzyme metabolism of these constituents can generate reactive intermediates that trigger oxidative stress and liver injury. Separately, ashwagandha's endocrine-modulating activity has been linked to thyrotoxicosis (excess thyroid hormone activity) and adrenal suppression, particularly with prolonged or high-dose use. Gastrointestinal disturbances and immune hypersensitivity reactions round out the adverse effect profile. The review flags specific drug interaction risks via CYP450 pathway competition, relevant for anyone on immunosuppressants, thyroid medications, or hepatically-cleared drugs.
This review is a valuable corrective to the near-universal enthusiasm surrounding ashwagandha, though its limitations matter. The evidence base remains heavily preclinical — animal and in vitro data — and human case reports of hepatotoxicity, while documented, are still relatively rare given global consumption volume. What's genuinely concerning is the absence of standardized dosing across commercial products, making exposure assessment unreliable. The thyroid-stimulating findings are particularly actionable for individuals with subclinical hyperthyroidism or those on levothyroxine. For the majority of healthy adults using low-to-moderate doses short-term, the risk-benefit ratio may still favor use — but this review makes a credible case that long-term, unsupervised consumption is not as benign as marketing implies.